In the CSCLC cases (groups 2–4), 2 mutations were identified : an EGFR mutation (L858R in exon 21) in the AD component of case 2 in Group 2, and a KRAS mutation (G12V in exon 2) in the SCLC component of case 2 in Group 3. This evidence concerns the gene EGFR and combined small cell lung carcinoma.